The potential utility of HERV elements as a screening tool or prognostic biomarker to be used in combination with PSA testing to identify high-risk cancers offers the opportunity to further improve prostate cancer prevention and minimise over-treatment of this common cancer. This evidence concerns the gene KLK3 and prostate carcinoma.